Published Articles & Presentations

The information in our publications and presentations should be considered accurate only as of the date of the publications or presentations. We disclaim any obligation to supplement or update the information in these publications and presentations.

To learn more about our innovative technology:

Publications Presentations

Precision Olfactory Delivery (POD®) of Drugs for Neurological Disease: A Safety, Tolerability and Comparative Bioavailability Study of POD Dihydroergotamine Mesylate (INP104) to Approved IV D.H.E. 45® and Migranal® Nasal Spray.

Impel NeuroPharma has developed the Precision Olfactory Delivery (POD® ) device to achieve consistent medicine delivery to the upper nasal cavity giving rapid uptake and higher bioavailability relative to standard nasal sprays. This study with dihydroergotamine mesylate (DHE) for migraine…

Cardiovascular Profile of Dihydroergotamine Mesylate (DHE) Delivered by the POD® Device Compared to D.H.E. 45® for Injection from the INP104-101 Clinical Trial

IV DHE is effective for acute migraine. The approved label warns of potential cardiovascular effects although the clinical experience of DHE in 70 years of use has been good. Work has shown the high Cmax of IV DHE may account…

Preclinical Development of a Novel Precision Olfactory Delivery (POD®) – L-dopa DrugDevice Combination Product for the Treatment of OFF Episodes in Parkinson’s Disease

Impel NeuroPharma has developed the POD device to generate rapid, consistent systemic levels of drugs for neurological diseases. This work was to develop a L-dopa powder formulation delivered by the POD device that results in plasma exposure in rats and…

26 27 28